| pubmed-article:11168989 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11168989 | lifeskim:mentions | umls-concept:C0022661 | lld:lifeskim |
| pubmed-article:11168989 | lifeskim:mentions | umls-concept:C0001128 | lld:lifeskim |
| pubmed-article:11168989 | lifeskim:mentions | umls-concept:C0001473 | lld:lifeskim |
| pubmed-article:11168989 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:11168989 | lifeskim:mentions | umls-concept:C0596235 | lld:lifeskim |
| pubmed-article:11168989 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
| pubmed-article:11168989 | pubmed:dateCreated | 2001-2-22 | lld:pubmed |
| pubmed-article:11168989 | pubmed:abstractText | Characterization of p-hydroxy-hippuric acid as an inhibitor of Ca2+-ATPase in end-stage renal failure. In patients with end-stage renal failure (ESRF), disturbances of Ca2+ metabolism are common. Besides hormonal changes, inhibition of cellular Ca2+-ATPase was postulated to contribute to uremic toxicity. We purified a potent inhibitor of the Ca2+-ATPase from the ultrafiltrate of patients with ESRF by multiple steps of high-performance liquid chromatography to homogeneity, and identified the isolated inhibitor by mass spectrometric methods as p-hydroxy-hippuric acid. The enzyme used for the Ca2+-ATPase assay system was isolated from red blood cells by cross-flow filtration. The activity of the Ca2+-ATPase was measured spectrophotometrically as the difference in hydrolysis of adenosine 5'-triphosphate (ATP) in the presence and absence of Ca2+ with different concentrations of ATP and p-hydroxyhippuric acid. The Ca2+-ATPase was found to be inhibited by p-hydroxy-hippuric acid at a concentration above 11.7 micromol/L. p-Hydroxyhippuric acid inhibited the erythrocyte Ca2+-ATPase by reducing Vmax and increasing the Km value. The EC50 (log mol/L; mean +/- SEM) for p-hydroxy-hippuric acid was calculated as 4.82 +/- 0.14. In conclusion, p-hydroxy-hippuric acid may play a role in disturbed Ca2+ metabolism in end-stage renal failure. | lld:pubmed |
| pubmed-article:11168989 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11168989 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11168989 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11168989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11168989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11168989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11168989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11168989 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11168989 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11168989 | pubmed:issn | 0098-6577 | lld:pubmed |
| pubmed-article:11168989 | pubmed:author | pubmed-author:SchlüterHH | lld:pubmed |
| pubmed-article:11168989 | pubmed:author | pubmed-author:JankowskiJJ | lld:pubmed |
| pubmed-article:11168989 | pubmed:author | pubmed-author:ZidekWW | lld:pubmed |
| pubmed-article:11168989 | pubmed:author | pubmed-author:TepelMM | lld:pubmed |
| pubmed-article:11168989 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:11168989 | pubmed:author | pubmed-author:StephanNN | lld:pubmed |
| pubmed-article:11168989 | pubmed:author | pubmed-author:BredenVV | lld:pubmed |
| pubmed-article:11168989 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11168989 | pubmed:volume | 78 | lld:pubmed |
| pubmed-article:11168989 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11168989 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11168989 | pubmed:pagination | S84-8 | lld:pubmed |
| pubmed-article:11168989 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:meshHeading | pubmed-meshheading:11168989... | lld:pubmed |
| pubmed-article:11168989 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11168989 | pubmed:articleTitle | Characterization of p-hydroxy-hippuric acid as an inhibitor of Ca2+-ATPase in end-stage renal failure. | lld:pubmed |
| pubmed-article:11168989 | pubmed:affiliation | Medizinische Klinik I, Universitäst-Klinik Marienhospital, Ruhr-Universität Bochum, Herne, Germany. | lld:pubmed |
| pubmed-article:11168989 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11168989 | pubmed:publicationType | In Vitro | lld:pubmed |
